Biote (BTMD) Total Operating Expense: $102.9 Mil (TTM As of Mar. 2026)


BTMD Biote Corp BTMD
66 GF Score
Price $2.01
GF Value $3.07
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Biote Total Operating Expense?

Biote BTMD 66 Total Operating Expense is $102.9 Mil as of Mar. 2026. GuruFocus rates BTMD with a GF Score™ of 66/100 and a GF Value™ of $3.07 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Biote's Total Operating Expense for the three months ended in Mar. 2026 was $27.8 Mil. Biote's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $102.9 Mil.

Biote Total Operating Expense Related Terms

Biote Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Biote's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biote Total Operating Expense Chart

Biote Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 56.02 171.10 98.83 107.45 101.81

Biote Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.69 24.22 26.15 24.74 27.79
BTMD
66GF Score
Biote Corp BTMD
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biote Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $102.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $102.9 Mil mean?
Biote (BTMD) has a Total Operating Expense of $102.9 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Biote and its competitors.
Is Biote's Total Operating Expense too high?
Biote's current Total Operating Expense is $102.9 Mil. Overall, Biote has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biote's Total Operating Expense compare to DCGO and PIII?
Biote's Total Operating Expense of $102.9 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Healthcare Providers & Services company?
A good Total Operating Expense depends on the Healthcare Providers & Services industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Biote and its competitors. Biote's current Total Operating Expense is $102.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biote stock overvalued right now?
Based on GuruFocus' analysis, Biote (BTMD) is currently considered Significantly Undervalued. The stock's GF Value™ is $3.07, compared to a current price of $2.01 — trading 34.5% below its estimated fair value. The current Total Operating Expense is $102.9 Mil. Biote's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Biote (BTMD), the current Total Operating Expense is $102.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biote (BTMD) Overvalued in 2026?

Based on GuruFocus' analysis, Biote stock appears to be undervalued. The current stock price of $2.01 is trading 34.5% below its estimated GF Value™ of $3.07. GuruFocus considers Biote to be Significantly Undervalued.

Key valuation signals for BTMD:

  • Total Operating Expense: $102.9 Mil
  • GF Value™: $3.07 vs. price of $2.01 (34.5% below fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the BTMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biote Business Description

Address 1875 W. Walnut Hill Lane, Suite 100, Irving, TX, USA, 75038
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
66GF Score

Get the complete analysis for BTMD

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.01
Price
$3.07
GF Value